The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Predicting clinical outcomes in the S1314-COXEN trial using a multimodal deep learning model integrating histopathology, cell types, and gene expression.
 
Bishoy Morris Faltas
Honoraria - Digital Science Press
Consulting or Advisory Role - Astrin Biosciences; Astrin Biosciences; BostonGene; BostonGene; Guardant Health; Immunomedics; Immunomedics; Janssen; Janssen; Merck; QED Therapeutics; QED Therapeutics; Seagen; Seagen
Research Funding - Lilly
Patents, Royalties, Other Intellectual Property - Patent royalties/Immunomedics
Travel, Accommodations, Expenses - Guardant Health; Guardant Health
 
Zilong Bai
No Relationships to Disclose
 
Mohamed Osman
No Relationships to Disclose
 
Matthew Brendel
No Relationships to Disclose
 
Catherine Tangen
No Relationships to Disclose
 
Thomas W. Flaig
Leadership - Aurora Oncology; University of Colorado/UC Health
Stock and Other Ownership Interests - Aurora Oncology
Consulting or Advisory Role - Janssen Oncology; Seagen
Research Funding - Agensys; Aragon Pharmaceuticals; Astellas Pharma; astrazeneca/MedImmune; Bavarian Nordic; Bristol-Myers Squibb; Criterium; Dendreon; Exelixis; GTx; Janssen Oncology; La Roche-Posay; Lilly; Medivation; Merck; Myovant Sciences; Novartis; Pfizer; Roche/Genentech; Sanofi; Seagen; Seagen; Sotio; Tokai Pharmaceuticals
Patents, Royalties, Other Intellectual Property - The University of Colorado has filed 2 patents in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or in active clinical development right now (e.g. neither are in clinical trials).
 
Ian M. Thompson
Leadership - H-E-B (grocery store chain)
Consulting or Advisory Role - Magforce
Research Funding - MagForce
Patents, Royalties, Other Intellectual Property - I have several patents with colleagues involving novel biomarkers for cancer and two devices for sexual dysfunction and urinary incontinence. No revenues at this time and our University IP office is working with industry to determine if these can be comme
 
Melissa Plets
No Relationships to Disclose
 
M. Scott Lucia
Stock and Other Ownership Interests - 3D Biopsy
 
Dan Theodorescu
Stock and Other Ownership Interests - Machavert Pharmaceuticals; Urogen Pharma
Consulting or Advisory Role - Machavert Pharmaceuticals
Patents, Royalties, Other Intellectual Property - ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME Pub No. US 2017/0204112 A1 Pub. Date: July 20,2017
 
Daniel Gustafson
No Relationships to Disclose
 
Siamak Daneshmand
Stock and Other Ownership Interests - Taris
Honoraria - Aduro Biotech; Allergan (I); Bausch and Lomb (I); Bristol-Myers Squibb; CG Oncology; Ferring; Janssen Oncology; Johnson & Johnson; Olympus; pacific edge; Pfizer; Photocure; Protara Therapeutics; QED Therapeutics
Consulting or Advisory Role - Ferring; Photocure; QED Therapeutics; Taris
Research Funding - Photocure
Travel, Accommodations, Expenses - Janssen Oncology; Photocure
 
Joshua J Meeks
Honoraria - Astellas Pharma; AstraZeneca; Imvax; incyte; Janssen; Merck; Pfizer; Prokarium; Urogen pharma
Research Funding - Epizyme; Merck Sharp & Dohme
Patents, Royalties, Other Intellectual Property - NMIBC genetic classifier (Inst); TCGA Classifier (Inst)
Other Relationship - Olympus
 
Woonyoung Choi
Research Funding - Janssen
 
Colin P.N. Dinney
Honoraria - AstraZeneca; CG Oncology
Consulting or Advisory Role - AstraZeneca; CG Oncology; NCI
Research Funding - CG Oncology; NCI
Patents, Royalties, Other Intellectual Property - Creator of intellectual property owned by UT/MDACC related to the use of genetic alterations as a predictive biomarker for response to Nadofaragene firadenovec
 
Olivier Elemento
Stock and Other Ownership Interests - OneThree Biotech; Owkin; Volastra Therapeutics
 
Seth P. Lerner
Stock and Other Ownership Interests - Aura Biosciences; C2i genomics
Honoraria - Grand Rounds in Urology; UroToday
Consulting or Advisory Role - AstraZeneca; Aura Biosciences; Bristol-Myers Squibb Foundation/Janssen; C2i Genomics; Ferring; Pfizer/EMD Serono; Protara Therapeutics; Stimit; Vaxiion; Verity Pharmaceuticals
Research Funding - Endo Pharmaceuticals; FKD Therapies; Japan BCG Laboratory; QED Therapeutics; Roche/Genentech; Vaxiion; Viventia Biotech
Patents, Royalties, Other Intellectual Property - TCGA expression subtype singel patient classifier
Other Relationship - Bladder Cancer Journal; UpToDate
 
David James McConkey
Honoraria - H3 Biomedicine; Janssen Oncology
 
Fei Wang
Employment - IBM (I)
Research Funding - Regeneron; Sanofi